Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 8, Issue 4

February 27 2024

In this Issue

INSIDE BLOOD ADVANCES
ADVANCES VIEWPOINT
SYSTEMATIC REVIEW
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
VASCULAR BIOLOGY
RESEARCH LETTERS
COMMENTARY
ERRATUM

INSIDE BLOOD ADVANCES

Maybe you can’t drive this CAR?

Benjamin A. Derman

View Articletitled, Maybe you can’t drive this CAR?

Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations

Safia Belbachir,Duncan Purtill

View Articletitled, Bridging therapy before axi-cel for lymphoma

ADVANCES VIEWPOINT

A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

Kevin J. Curran,Sarah Nikiforow,Carlos Bachier,Yen-Michael Hsu,David Maloney,Marcela V. Maus,Philip McCarthy,David Porter,Patricia Shi,Elizabeth J. Shpall,Basem William,Kara Wacker,Phyllis Warkentin,Helen E. Heslop

View Articletitled, A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help

SYSTEMATIC REVIEW

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
Clinical Trials & Observations

Connor Prosty,Khaled Katergi,Alex Nguyen,Owen Dan Luo,Mark Sorin,Vladimir Cherniak,Michael Sebag,Koray Demir,Emily G. McDonald,Todd C. Lee,Matthew P. Cheng

View Articletitled, Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Clinical Trials & Observations

Inhye E. Ahn,Danielle M. Brander,Yue Ren,Yinglu Zhou,Svitlana Tyekucheva,Heather A. Walker,Robert Black,Josie Montegaard,Alvaro Alencar,Leyla Shune,Mohammad Omaira,Caron A. Jacobson,Philippe Armand,Samuel Y. Ng,Jennifer Crombie,David C. Fisher,Ann S. LaCasce,Jon Arnason,Ephraim P. Hochberg,Ronald W. Takvorian,Jeremy S. Abramson,Jennifer R. Brown,Matthew S. Davids

View Articletitled, Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Supplemental data

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Clinical Trials & Observations

Tycel J. Phillips,Abraham Avigdor,Ronit Gurion,Caterina Patti,Paolo Corradini,Monica Tani,Amitkumar Mehta,Izidore S. Lossos,Pier Luigi Zinzani,Catherine Thieblemont,Wojciech Jurczak,Fred Zheng,Erica Rappold,Wanying Zhao,Ping Jiang,Peter Johnson

View Articletitled, A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Supplemental data

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Clinical Trials & Observations

Rohan Shotton,Rachel Broadbent,Alia Alchawaf,Mohamed Bakri Mohamed,Adam Gibb,Nicolás Martinez-Calle,Christopher P. Fox,Mark Bishton,Alexandra Pender,Mary Gleeson,David Cunningham,Andrew Davies,Sina Yadollahi,Toby A. Eyre,Graham Collins,Faouzi Djebbari,Shireen Kassam,Paula Garland,Emily Watts,Wendy Osborne,William Townsend,Rachael Pocock,Matthew J. Ahearne,Fiona Miall,Xin Wang,Kim M. Linton

View Articletitled, Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience

Supplemental data

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Clinical Trials & Observations

Nicholas J. Short,Elias Jabbour,Nitin Jain,Jayastu Senapati,Lewis Nasr,Fadi G. Haddad,Zhenhua Li,Yu-Chih Hsiao,Jun J. Yang,Naveen Pemmaraju,Maro Ohanian,William G. Wierda,Guillermo Montalban-Bravo,Gautam Borthakur,Lina Han,Lianchun Xiao,Xuelin Huang,Regina Abramova,Min Zhao,Rebecca Garris,Marina Konopleva,Farhad Ravandi,Hagop Kantarjian

View Articletitled, A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Supplemental data

Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Clinical Trials & Observations

Romit Bhattacharya,Md Mesbah Uddin,Aniruddh P. Patel,Abhishek Niroula,Phoebe Finneran,Rachel Bernardo,Kathleen V. Fitch,Michael T. Lu,Gerald S. Bloomfield,Carlos Malvestutto,Judy A. Aberg,Carl J. Fichtenbaum,Whitney Hornsby,Heather J. Ribaudo,Peter Libby,Benjamin L. Ebert,Markella V. Zanni,Pamela S. Douglas,Steven K. Grinspoon,Pradeep Natarajan

View Articletitled, Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial

Supplemental data

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Clinical Trials & Observations

Jacqueline S. Garcia,Haesook T. Kim,H. Moses Murdock,Michela Ansuinelli,Jennifer Brock,Corey S. Cutler,Mahasweta Gooptu,Vincent T. Ho,John Koreth,Sarah Nikiforow,Rizwan Romee,Roman Shapiro,Daniel J. DeAngelo,Richard M. Stone,Denbaa Bat-Erdene,Jeremy Ryan,Manuel E. Contreras,Geoffrey Fell,Anthony Letai,Jerome Ritz,R. Coleman Lindsley,Robert J. Soiffer,Joseph H. Antin

View Articletitled, Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Supplemental data

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Clinical Trials & Observations

Michael D. Jain,Miriam T. Jacobs,Feng Gao,Loretta J. Nastoupil,Jay Y. Spiegel,Yi Lin,Saurabh Dahiya,Matthew Lunning,Lazaros Lekakis,Patrick Reagan,Olalekan Oluwole,Joseph McGuirk,Abhinav Deol,Alison R. Sehgal,Andre Goy,Brian T. Hill,Charalambos Andreadis,Javier Munoz,Julio C Chavez,N. Nora Bennani,Aaron P. Rapoport,Julie M. Vose,David Miklos,Sattva S. Neelapu,Frederick L. Locke,Armin Ghobadi

View Articletitled, Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Supplemental data

Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations

Safia Belbachir,Duncan Purtill

View Articletitled, Bridging therapy before axi-cel for lymphoma

HEMATOPOIESIS AND STEM CELLS

Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy

Seunga Choo,Carl B. Wolf,Heather M. Mack,Mitchell J. Egan,Hans-Peter Kiem,Stefan Radtke

View Articletitled, Choosing the right mouse model: comparison of humanized NSG and NBSGW mice for in vivo HSC gene therapy

Supplemental data

LYMPHOID NEOPLASIA

MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study

Chiara Pagani,Chiara Rusconi,Alessia Dalla Pria,Emanuele Ravano,Philipp Schommers,Mariana Bastos-Oreiro,Luisa Verga,Guido Gini,Michele Spina,Luca Arcaini,Sara Steffanoni,Davide Dalu,Lara Crucitti,Luisa Lorenzi,Piera Balzarini,Chiara Cattaneo,Lucia Bongiovanni,Andreas Rosenwald,Fabio Facchetti,Mark Bower,Andrés J. M. Ferreri,Giuseppe Rossi,Alessandra Tucci,Alessandro Re

View Articletitled, MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study

MYELOID NEOPLASIA

High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer

Aaron J. Stonestrom,Kamal N. Menghrajani,Sean M. Devlin,Sebastià Franch-Expósito,Ryan N. Ptashkin,Swara Y. Patel,Barbara Spitzer,Xiaodi Wu,Justin Jee,Pablo Sánchez Vela,Jennifer H. Milbank,Ronak H. Shah,Abhinita S. Mohanty,A. Rose Brannon,Wenbin Xiao,Michael F. Berger,Simon Mantha,Ross L. Levine

View Articletitled, High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer

Supplemental data

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Clinical Trials & Observations

Alex Bataller,Alexandre Bazinet,Courtney D. DiNardo,Abhishek Maiti,Gautam Borthakur,Naval G. Daver,Nicholas J. Short,Elias J. Jabbour,Ghayas C. Issa,Naveen Pemmaraju,Musa Yilmaz,Guillermo Montalban-Bravo,Koichi Takahashi,Sanam Loghavi,Guillermo Garcia-Manero,Farhad Ravandi,Hagop M. Kantarjian,Tapan M. Kadia

View Articletitled, Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia

Ramanagouda Ramanagoudr-Bhojappa,Rebecca Tryon,Francis P. Lach,Frank X. Donovan,Rochelle Maxwell,Allana Rosenberg,Margaret L. MacMillan,John E. Wagner,Arleen D. Auerbach,Agata Smogorzewska,Settara C. Chandrasekharappa

View Articletitled, FANCA c.3624C>T (p.Ser1208=) is a hypomorphic splice variant associated with delayed onset of Fanconi anemia

Supplemental data

Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel

Deva Sharma,Ilknur Kozanoğlu,Kenneth I. Ataga,Alexandra Benachi,Selim Büyükkurt,Sophie Lanzkron,Hakan Ozdogu,Shivan Pancham,Lydia H. Pecker,Susan E. Robinson,Safak Yilmaz Baran,Jo Howard

View Articletitled, Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel

Supplemental data

THROMBOSIS AND HEMOSTASIS

A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation

Romy M. W. de Laat-Kremers,Denis Wahl,Stéphane Zuily,Marisa Ninivaggi,Véronique Regnault,Jacek Musial,Philip G. de Groot,Katrien M. J. Devreese,Bas de Laat

View Articletitled, A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation

Supplemental data

TRANSPLANTATION

CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model

Lotus Neidemire-Colley,Shrijan Khanal,Kara M. Braunreiter,Yandi Gao,Rathan Kumar,Katiri J. Snyder,Margot A. Weber,Simran Surana,Olimjon Toirov,Malith Karunasiri,Molly E. Duszynski,Mengna Chi,Punam Malik,Sonu Kalyan,Wing K. Chan,Meisam Naeimi Kararoudi,Hannah K. Choe,Ramiro Garzon,Parvathi Ranganathan

View Articletitled, CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model

Supplemental data

Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients

Matt S. Zinter,Ruta Brazauskas,Joelle Strom,Stella Chen,Stephanie Bo-Subait,Akshay Sharma,Amer Beitinjaneh,Dimana Dimitrova,Greg Guilcher,Jaime Preussler,Kasiani Myers,Neel S. Bhatt,Olle Ringden,Peiman Hematti,Robert J. Hayashi,Sagar Patel,Satiro Nakamura De Oliveira,Seth Rotz,Sherif M. Badawy,Taiga Nishihori,David Buchbinder,Betty Hamilton,Bipin Savani,Hélène Schoemans,Mohamed Sorror,Lena Winestone,Christine Duncan,Rachel Phelan,Christopher C. Dvorak

View Articletitled, Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients

Supplemental data

VASCULAR BIOLOGY

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Lulu Huang,Yuji Kondo,Lijuan Cao,Jingjing Han,Tianyi Li,Bin Zuo,Fei Yang,Yun Li,Zhenni Ma,Xia Bai,Miao Jiang,Changgeng Ruan,Lijun Xia

View Articletitled, Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Supplemental data

RESEARCH LETTERS

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Clinical Trials & Observations

Marco Herling,Claire Dearden,Francesco Zaja,Dima El-Sharkawi,Wei Ding,Mar Bellido,Amit Khot,Lidwine Tick,Eric Jacobsen,Toby A. Eyre,Damien Roos-Weil,Tapan Kadia,Elisa Lucchini,Natali Pflug,Matthew S. Davids,German Pena,Nabanita Mukherjee,Mohamed Badawi,Tamas Vizkelety,Philipp B. Staber

View Articletitled, Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Supplemental data

A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
Clinical Trials & Observations

Zhibo Zhang,Jia Yin,Guoli Lian,Xiebing Bao,Meng Hu,Zhenfang Liu,Yuan Yu,Ruihua Mi,Yabei Zuo,Pengcheng Shi,Weiyan Zheng,Qian Jiang,Hongying Chao,Peifang Xiao,Weijuan Yu,Yanqiu Han,Yu Wu,Yan Zeng,Depei Wu,Xiaofei Yang,Suning Chen

View Articletitled, A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML

Supplemental data

Estimation of eligibility for and response to CAR-T therapy in the United States

Alyson Haslam,Tracy Beth Hoeg,Vinay Prasad

View Articletitled, Estimation of eligibility for and response to CAR-T therapy in the United States

Maybe you can’t drive this CAR?

Benjamin A. Derman

View Articletitled, Maybe you can’t drive this CAR?

Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies

Helen Ma,Jia Y. Wan,Victoria K. Cortessis,Pankaj Gupta,Wendy Cozen

View Articletitled, Survival in Agent Orange exposed and unexposed Vietnam-era veterans who were diagnosed with lymphoid malignancies

Supplemental data

COMMENTARY

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Clinical Trials & Observations

Rahul Banerjee,Christina Poh,Alexandre V. Hirayama,Jordan Gauthier,Ryan D. Cassaday,Mazyar Shadman,Andrew J. Cowan,Brian G. Till,Damian J. Green,Hans-Peter Kiem,Ajay K. Gopal,David G. Maloney

View Articletitled, Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

ERRATUM

Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.

View Articletitled, Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023;7(20):6266-6274.

Cover Image

Cover Image

NOD/SCID/IL2rγ^null (NSG) mice were irradiated (100 cGy) and transplanted with control T cells or CRISPR/Cas9–edited MIR155HGΔexon3 human T cells. Hematoxylin and eosin staining show control human T-cell infiltration (purple) in a skin section from a recipient mouse with acute graft-versus-host disease (GVHD). NSG mice that received MIR155HG^Δexon3 human T cells exhibit reduced T-cell infiltration in target organs and are protected from lethal GVHD. See the article by Neidemire-Colley et al.

All Issues

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

CAR T-cell Therapy in Mantle Cell Lymphoma with Secondary CNS Involvement - a multicenter experience.

Risk of T-cell Malignancy Following CAR T cells in Children, Adolescents and Young Adults

Essential role of glycoprotein Ibα in platelet activation

Extracellular release of mitochondria induced by pre-hematopoietic stem cell transplant conditioning exacerbates GVHD

Venetoclax, a new player in the treatment of children with high-risk myeloid malignancies?

Issue Archive

Table of Contents

INSIDE BLOOD ADVANCES

Bridging therapy before axi-cel for lymphoma Clinical Trials & Observations

ADVANCES VIEWPOINT

SYSTEMATIC REVIEW

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL Clinical Trials & Observations

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) Clinical Trials & Observations

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience Clinical Trials & Observations

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia Clinical Trials & Observations

Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial Clinical Trials & Observations

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML Clinical Trials & Observations

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium Clinical Trials & Observations

Bridging therapy before axi-cel for lymphoma Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax Clinical Trials & Observations

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

VASCULAR BIOLOGY

RESEARCH LETTERS

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study Clinical Trials & Observations

A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML Clinical Trials & Observations

COMMENTARY

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic Clinical Trials & Observations

ERRATUM

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs
Clinical Trials & Observations

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Clinical Trials & Observations

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Clinical Trials & Observations

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Clinical Trials & Observations

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Clinical Trials & Observations

Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Clinical Trials & Observations

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
Clinical Trials & Observations

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
Clinical Trials & Observations

Bridging therapy before axi-cel for lymphoma
Clinical Trials & Observations

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
Clinical Trials & Observations

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Clinical Trials & Observations

A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
Clinical Trials & Observations

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Clinical Trials & Observations